University of California San Francisco (UCSF)

University / College


Location: San Francisco, United States (USA) (US) US

ISNI: 0000000122976811

ROR: https://ror.org/043mz5j54

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

RELATION OF HIP ABDUCTOR STRENGTH TO WORSENING CARTILAGE DAMAGE IN THE KNEE: THE MULTICENTER OSTEOARTHRITIS STUDY (2021) Stefanik JJ, Felson DT, Rabasa G, Guermazi A, Römer W, Lynch J, Lewis CE, et al. Conference contribution Reactive astrocyte nomenclature, definitions, and future directions (2021) Escartin C, Galea E, Lakatos A, O’Callaghan JP, Petzold GC, Serrano-Pozo A, Steinhäuser C, et al. Journal article, Review article Reliability and change in erosion measurements by high-resolution peripheral quantitative computed tomography in a longitudinal dataset of rheumatoid arthritis patients (2021) Finzel S, Manske SL, Barnabe CC, Burghardt AJ, Marotte H, Scharmga A, Hauge EM, et al. Journal article Idecabtagene vicleucel in relapsed and refractory multiple myeloma (2021) Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, et al. Journal article A CD22-Shp1 phosphatase axis controls integrin beta(7) display and B cell function in mucosal immunity (2021) Ballet R, Brennan M, Brandl C, Feng N, Berri J, Cheng J, Ocon B, et al. Journal article Gut CD4+ T cell phenotypes are a continuum molded by microbes, not by TH archetypes (2021) Kiner E, Willie E, Schmutz H, Chandler J, Schnell A, Thakore PI, LeGros G, et al. Journal article Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane (2021) O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, et al. Conference contribution Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy (2021) Rugo H, Chow LWC, Cortes J, Fasching P, He XB, Hsu P, Huang CS, et al. Conference contribution Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial (2021) Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al. Journal article Trauma, a Matter of the Heart-Molecular Mechanism of Post-Traumatic Cardiac Dysfunction. (2021) Weber B, Lackner I, Gebhard F, Miclau T, Kalbitz M Journal article, Review article